Drug Profile


Alternative Names: DRF 2593

Latest Information Update: 13 Aug 2015

Price : $50

At a glance

  • Originator Dr Reddys Laboratories
  • Developer Dr Reddys Laboratories; Rheoscience
  • Class Antihyperglycaemics; Small molecules; Thiazolidinediones
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 17 Aug 2010 Clinical development is ongoing in Denmark
  • 05 Jan 2010 Efficacy and adverse events data from a phase III trial in Type-2 diabetes mellitus released by Dr. Reddy's Laboratories and Rheoscience
  • 22 Aug 2007 Phase-III clinical trials in Type-2 diabetes mellitus in Denmark (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top